Blog
KPV Peptide Guide: What It Is and What the Research Shows
KPV peptide, short for lysine-proline-valine, is a fragment of alpha-melanocyte-stimulating hormone (a-MSH) that researchers study in cell and animal models, mainly of inflammation. The sections below cover what the KPV peptide is, how it acts in the laboratory, what studies have observed, what remains unknown and what a KPV certificate analysis should show.
KPV is a peptide for research purposes only and is not approved by the FDA for human use.
What is KPV peptide?
Three findings describe how KPV acts in the laboratory. Each comes from a different model.
- Entry through PepT1: In human intestinal and T-cell lines, KPV entered cells through PepT1, a transporter that carries small peptides across cell membranes. At nanomolar concentrations, it reduced NF-kB activity (NF-kB is a protein complex which switches on inflammatory genes) and MAP kinase signalling (Dalmasso et al., 2008)
- Not tied to one receptor: In mouse colitis, KPVās effects appeared to be at least partly independent of the MC1 receptor. Mice without a working MC1 receptor who received KPV all survived DSS-induced colitis. (Kannengiesser et al., 2008).
- A route into the nucleus: In a human bronchial epithelial cell line, KPV entered the cell nucleus and appeared to compete with the NF-kB subunit p65 for binding to importin-a3, a protein that carries p65 into the nucleus. (Land 2012)
These are proposals from separate models. The FDA briefing states that the molecular targets behind KPVās effect remain unknown and that melanocortin receptors are unlikely to be among them. In intestinal cell work, lower NF-kB activity correlated with lower cytokine release, the signalling proteins that carry inflammatory messages between cells.
KPV peptide benefits: What research has observed
| Area | Model | What was observed | Source |
| Gut Inflammation | Mouse Colitis models (DSS, TNBS and transfer colitis) | Less inflammatory infiltrate and lower MPO activity (an enzyme marker of neutrophil activity in tissue). Oral KPV lowered colitis incidence | Dalmasso 2008; Kannengiesser 2008 |
| Airway cells | Human bronchial epithelial cell line | Suppressed NF-kB signalling triggered by TNFĪ±, an inflammatory protein, or by respiratory syncytial virus | Land 2012 |
| Wound Healing | Rabbit corneal abrasion, topical KPV | Authors reported that KPV may facilitate healing of the epithelial wound. A nitric oxide inhibitor blocked the effect | Bonfiglio 2006 |
| Antimicrobial activityĀ | Laboratory cultures of S. aureus and C. albicans | Reduced S. aureus colony formation and C. albicans viability, reported in one early studyĀ | Cutuli 2000 |
| Skin Penetration | Human cadaver skin, in vitroĀ | Poor penetration through skin. Iontophoresis (a small electrical current) or microneedles increased it.Ā | Pawar 2017, as summarised in the FDA briefing |
The results of these studies are from cells and animals and do not show the side effects of KPV peptide in humans.
KPV peptide uses in research
Laboratories use KPV in colitis and wound healing models and in studies of NF-kB signalling. As a tripeptide, KPV is also used to study PepT1 uptake, and skin delivery studies use it to test ways of moving a peptide through skin.
Cell- line work measures cytokine release and signalling proteins, while animal work measures tissue inflammation, MPO activity and body weight.
What is still unknown about KPV
No human studies: The FDA briefing identified no clinical studies, human exposure data or human pharmacokinetic studies of KPV by any route. The searches covered PubMed, Embase and ClinicalTrials.gov, and its evaluation of 0.1% KPV cream and gel formulations found no information on KPV given to humans.
Human safety is unknown; FDA also identified no acute toxicity, repeat-dose toxicity or genotoxicity studies of KPV.
What to look for in a KPV certificate of analysis
A certificate of analysis (CoA) is the laboratory report for one batch. The FDA briefing describes KPV as poorly characterised: it is sold under inconsistent names, as both a free base and an acetate salt, and most free base certificates the agency found reported purity only.
A KPV certificate should state:
- Batch number and test date
- The laboratory that ran the analysis
- Purity by HPLC: high-performance liquid chromatography separates a sample into its components, so the share of the target peptide can be measured
- Measured Content: The amount of peptide in the vial, not only a percentage purity
Why get KPV peptides from River Peptides?
River Peptides sends samples from every new batch to independent laboratories, including Janoshik Laboratories and Analiza Bialek. HPLC (high-performance liquid chromatography) confirms purity and detects related substances, and mass spectrometry verifies compound identity. The batch ID printed on each label locates the matching certificate of analysis.Ā We offer KPV (LysineāProlineāValine) 10mg and also a KPV 10mg spray for research.Ā
River Peptides also holds ISO 9001 and ISO 14001 accreditation, covering quality management and environmental management respectively. The full process is on the quality testing page.Ā Ā Ā
KPV peptides FAQs
What is the KPV peptide dosage?
No validated dose amount exists,s as no human studies have been identified.
Does KPV peptide have side effects?
Human side effects are unknown, as no human safety data have been identified.
Is KPV the same as BPC-157?
No. They are different peptides: KPV has three amino acids and BPC-157 has 15. Our KPV vs BPC-157 research comparison guide covers the differences in more detail, and the BPC-157 product page lists its specifications.Ā
Is KPV part of the Klow Stack?
Yes. The Klow Stack is the Glow Stack (BPC-157, TB-500 and GHK-Cu) with KPV added, and River Peptides supplies it as separate vials. Our Glow Stack vs Klow Stack guide explains how the two combinations differ. This guide covers KPV research on its own, not in combination with other peptides.
Is KPV a steroid?
No. KPV is a peptide, and steroids are a different class of molecule, built on a four-ring carbon structure.
